Publication date: Jan 14, 2020
One of the most frequently found mutations in human melanomas is in the B-raf gene, making its protein BRAF a key target for therapy. However, in patients treated with BRAF inhibitor (BRAFi), although the response is very good at first, relapse occurs within 6 months, on the average. In order to overcome this drug resistance to BRAFi, various combinations of BRAFi with other drugs have been explored, and some are being applied clinically, such as a combination of BRAF and MEK inhibitors. Experimental data for melanoma in mice show that under continuous treatment with BRAFi, the pro-cancer MDSCs and chemokine CCL2 initially decrease but eventually increase to above their original level, while the anticancer T cells continuously decrease. In this paper, we develop a mathematical model that explains these experimental results. The model is used to explore the efficacy of combinations of BRAFi with anti-CCL2, anti-PD-1 and anti-CTLA-4, with the aim of eliminating or reducing drug resistance to BRAFi.
Friedman, A. and Siewe, N. Overcoming Drug Resistance to BRAF Inhibitor. 25451. 2020 Bull Math Biol (82):1.
|BRAF Inhibitor||Clinical medicine|
- Pleural metastasis from auricular melanoma: A brief report.
- Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity.
- Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma.
- Principles of Targeted Therapy for Melanoma.
- NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
- T-Type calcium channels as potential therapeutic targets in vemurafenib-resistant BRAF melanoma: TTCCs are therapy target in BRAF melanoma.
- Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.
- Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.